News and Updates

Medtronic’s Extended Wear Infusion Set (EWIS) is the first infusion set approved for 7 days, a significantly longer duration; Currently, no other infusion set is approved for more than 3 days.

Vertex is currently enrolling for a clinical trial evaluating their stem cell derived islet cell infusion therapy, VX-880.

Breakthrough T1D and NIH bring together top scientists and engineers to strategize on how to allow implanted beta cells to thrive.

On August 2, 2021, Abbott announced the FreeStyle Libre 2 iOS app received approval from the FDA for adults and children ages 4 and up with diabetes.

The U.S. Food and Drug Administration (FDA) approved Semglee® (insulin glargine-yfgn) as the first ever interchangeable biosimilar insulin product. Semglee® (insulin glargine-yfgn) is indicated to improve glycemic control in adults and pediatric people with type 1 and adults with type 2 diabetes, and is biosimilar and interchangeable to Lantus®, a long-acting insulin. In other words, […]

Two recent publications shed light on which people with type 1 diabetes will develop end-stage kidney disease, a complication of diabetes.

Breakthrough T1D is excited to announce that the T1D Fund portfolio company Protomer Technologies, who is developing "smart" insulin, has been acquired by Eli Lilly.

The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.

There were a number of fantastic results at the ADA’s Scientific Sessions. Here is a video and a summary of the key takeaways from the conference.

Here is Dr. Camillo Ricordi to share his key takeaways from day 4 from the American Diabetes Association's Scientific Sessions.